BRIDGEWATER, N.J.--(BUSINESS WIRE)--CorMedix Inc. (“CorMedix”) (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, received a notice from the NYSE MKT on April 5, 2013 indicating that it is below listing standard criteria. In its Form 10-K for the fiscal year ended December 31, 2012. CorMedix reported stockholders’ equity of less than $2 million and did not meet certain of the NYSE MKT continued listing standards as set forth in the NYSE MKT Company Guide.